Sitemap


Technology-PET icon

Technology

See why today’s PCa imaging is suboptimal and reimagine it with PET1

Learn more >
Technology-PET icon

Technology

See why today’s PCa imaging is suboptimal and reimagine it with PET1

Learn more >
Target-PSMA icon

Target

Discover how specific targeting of PSMA may result in improved diagnostic accuracy2,3

Learn more >
Target-PSMA icon

Target

Discover how specific targeting of PSMA may result in improved diagnostic accuracy2,3

Learn more >
Tracer-18F icon

Tracer

Explore how the high spatial resolution and low positronic emission of 18F may result in high‑quality images6

Learn more >
Tracer-18F icon

Tracer

Explore how the high spatial resolution and low positronic emission of 18F may result in high‑quality images6

Learn more >
Tools-AI systems icon

Tools

Consider the potential of increasing the consistency and accuracy of image reporting with AI systems5,7

Learn more >
Tools-AI systems icon

Tools

Consider the potential of increasing the consistency and accuracy of image reporting with AI systems5,7

Learn more >

References:
1. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019;11:1-14. doi:10.1177/1758835919876828.
2. Petersen L, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer; an expedited systematic review. Cancer Imaging. 2020;1-8. doi:10.1186/s40644-020-0290-9
3. Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. /doi.org/10.1148/radiol.2020191689
4. Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1‐16.
5. Duffy IR, Boyle AJ, Vasdev N. Improving PET imaging acquisition and analysis with machine learning: a narrative review with focus on alzheimer’s disease and oncology. Molecular Imaging. 2019;18:1-11. doi:10.1177/1536012119869070
6. Data on file. Progenics Pharmaceuticals, Inc.